Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10/L to <100 × 10/L) at baseline: the final analysis of EXPAND

Efficacy and safety of ruxolitinib in patients with myelofibrosis and low platelet count (50 × 10/L to <100 × 10/L) at baseline: the final analysis of EXPAND

Background: Thrombocytopenia is a common feature of myelofibrosis (MF), a myeloproliferative neoplasm driven by dysregulated JAK/STAT signaling; however, pivotal trials assessing the efficacy of ruxolitinib (a JAK1/2 inhibitor) excluded MF patients with low platelet counts (<100 × 10 9 /L). Objec...

Full description

Bibliographic Details
Main Authors: Paola Guglielmelli, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Minghui Duan, Haitao Meng, Ling Pan, Guangsheng He, Srdan Verstovsek, Françoise Boyer, Fiorenza Barraco, Dietger Niederwieser, Ester Pungolino, Anna Marina Liberati, Claire Harrison, Pantelia Roussou, Monika Wroclawska, Divyadeep Karumanchi, Karen Sinclair, Peter A.W. te Boekhorst, Heinz Gisslinger
Format: Article
Language:English
Published: SAGE Publishing 2022-09-01
Series:Therapeutic Advances in Hematology
Online Access:https://doi.org/10.1177/20406207221118429

Internet

https://doi.org/10.1177/20406207221118429

Similar Items